| Discovery of a dihydroisoquinolinone derivative (NVP-CGM097): a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors P Holzer, K Masuya, P Furet, J Kallen, T Valat-Stachyra, S Ferretti, ... Journal of medicinal chemistry 58 (16), 6348-6358, 2015 | 196 | 2015 |
| Fundamental aspects of DMPK optimization of targeted protein degraders C Cantrill, P Chaturvedi, C Rynn, JP Schaffland, I Walter, MB Wittwer Drug discovery today 25 (6), 969-982, 2020 | 117 | 2020 |
| A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097 S Jeay, S Gaulis, S Ferretti, H Bitter, M Ito, T Valat, M Murakami, S Ruetz, ... Elife 4, e06498, 2015 | 82 | 2015 |
| In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics AP MacGowan, C Rynn, M Wootton, KE Bowker, HA Holt, DS Reeves Clinical microbiology and infection 5 (1), 32-36, 1999 | 62 | 1999 |
| Membrane transporters: Fundamentals, function and their role in ADME J Keogh, B Hagenbuch, C Rynn, B Stieger, G Nicholls | 24 | 2016 |
| In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor A Vaupel, P Holzer, S Ferretti, V Guagnano, J Kallen, R Mah, K Masuya, ... Bioorganic & medicinal chemistry letters 28 (20), 3404-3408, 2018 | 23 | 2018 |
| Discovery of novel allosteric EGFR L858R inhibitors for the treatment of non-small-cell lung cancer as a single agent or in combination with osimertinib U Obst-Sander, A Ricci, B Kuhn, T Friess, P Koldewey, A Kuglstatter, ... Journal of medicinal chemistry 65 (19), 13052-13073, 2022 | 12 | 2022 |
| Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats AD Forkuo, C Ansah, D Pearson, W Gertsch, A Cirello, A Amaral, J Spear, ... BMC Pharmacology and Toxicology 18, 1-9, 2017 | 11 | 2017 |
| Preclinical characterization of a next-generation brain permeable, paradox breaker BRAF inhibitor J Wichmann, C Rynn, T Friess, J Petrig-Schaffland, M Kornacker, C Handl, ... Clinical Cancer Research 28 (4), 770-780, 2022 | 10 | 2022 |
| Discovery of NVP-HDM201-First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics P Holzer, P Chène, S Ferretti, P Furet, T Gabriel, B Gruenenfelder, ... Cancer Research 76 (14_Supplement), 4855-4855, 2016 | 8 | 2016 |
| NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2 S Jeay, P Chène, S Ferretti, P Furet, B Gruenenfelder, V Guagnano, ... Cancer Research 76 (14_Supplement), 1225-1225, 2016 | 6 | 2016 |
| Industry perspective on the pharmacokinetic and ADME characterization of heterobifunctional protein degraders LP Volak, HM Duevel, S Humphreys, D Nettleton, C Phipps, A Pike, ... Drug metabolism and disposition, 2023 | 5 | 2023 |
| Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial S Jeay, J Berghausen, N Buschmann, P Chène, R Cozens, D Erdmann, ... Cancer Research 74 (19_Supplement), 1797-1797, 2014 | 4 | 2014 |
| Translating pharmacology models effectively to predict therapeutic benefit S Dudal, C Bissantz, A Caruso, P David-Pierson, W Driessen, E Koller, ... Drug Discovery Today 27 (6), 1604-1621, 2022 | 3 | 2022 |
| Correction: a distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097 S Jeay, S Gaulis, S Ferretti, H Bitter, M Ito, T Valat, M Murakami, S Ruetz, ... Elife 5, e19317, 2016 | 3 | 2016 |
| Abstract DDT01-01: Discovery of CGM097 as a novel Mdm2 inhibitor K Masuya, P Furet, S Stutz, P Holzer, C Pissot-Soldmann, N Buschmann, ... Cancer Research 74 (19_Supplement), DDT01-01-DDT01-01, 2014 | 3 | 2014 |
| Design and synthesis of inhibitors of the E3 ligase SMAD specific E3 ubiquitin protein ligase 1 as a treatment for lung remodeling in pulmonary arterial hypertension DE Shaw, N Smith, R Beerli, S Cotesta, PL D’Alessandro, AM Edwards, ... Journal of medicinal chemistry 66 (12), 8130-8139, 2023 | 2 | 2023 |
| Chemical, Analytical and Pharmacokinetic Characterisation of RO7304898, an API Consisting of Two Rapidly Interconverting Diastereoisomers K Heinig, F Sladojevich, J Petrig Schaffland, G Jaeschke, A Ross, ... Pharmaceutical Research 39 (4), 653-667, 2022 | 1 | 2022 |
| Discovery of NVP-HDM201: Identification of a next-generation Mdm2 inhibitor with superior characteristics P Holzer, P Chene, S Ferretti, P Furet, T Gabriel, B Gruenenfelder, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 252, 2016 | 1 | 2016 |
| In vitro assessment of colistin's antimicrobial interactions with six other antimictobials studied using a representative strain of pseudomonas aeruginosa AP MacGowan, C Rynn, M Wootton, KE Bowker, HA Holt, DS Reeves Clinical Microbiology and Infection 5 (1), 32-36, 1999 | 1 | 1999 |
